Advertisement

Management of adrenocorticotropic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome

Published:April 15, 2022DOI:https://doi.org/10.1016/j.surg.2022.03.014

      Abstract

      Background

      Neuroendocrine tumors can cause ectopic Cushing syndrome, and most patients have metastatic disease at diagnosis. We identified risk factors for outcome, evaluated ectopic Cushing syndrome management, and explored the role of bilateral adrenalectomy in this population.

      Methods

      This was a retrospective study including patients with diagnosis of ectopic Cushing Syndrome secondary to neuroendocrine tumors with adrenocorticotropic hormone secretion treated at our quaternary referral center over a 40-year period (1980–2020).

      Results

      Seventy-six patients were included. Mean age at diagnosis was 46.3 ± 15.8 years. Most patients (N = 61, 80%) had metastases at ectopic Cushing syndrome diagnosis. Average follow-up was 2.9 ± 3.7 years (range, 4 months–17.2 years). Patients with neuroendocrine tumors before ectopic Cushing syndrome had more frequent metastatic disease and resistant ectopic Cushing syndrome. Patients with de novo hyperglycemia, poor neuroendocrine tumor differentiation, and metastatic disease had worse survival. Of those with nonmetastatic disease, 8 (53%) had ectopic Cushing syndrome resolution after neuroendocrine tumor resection, 3 (20%) were medically controlled, and 4 (27%) underwent bilateral adrenalectomy. In patients with metastatic neuroendocrine tumors, hypercortisolism was initially medically managed in 92%, 3% underwent immediate bilateral adrenalectomy, 2% had control after primary neuroendocrine tumor debulking, and 2% were lost to follow-up. Medical treatment resulted in hormonal control in 7 (13%) patients. Of the 49 patients with metastatic disease and medically resistant ectopic Cushing syndrome, 23 ultimately had bilateral adrenalectomy with ectopic Cushing syndrome cure in all.

      Conclusion

      Patients with neuroendocrine tumors before ectopic Cushing syndrome development were more likely metastatic and had worse survival. De novo hyperglycemia and poor neuroendocrine tumor differentiation were predictive of worse prognosis. Medical control of hypercortisolism is difficult to achieve in patients with neuroendocrine tumors–ectopic Cushing syndrome. Well-selected patients may benefit from bilateral adrenalectomy early in the treatment algorithm, and multidisciplinary management is essential in this complex disease.

      Graphical abstract

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ejaz S.
        • Vassilopoulou-Sellin R.
        • Busaidy N.L.
        • et al.
        Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center experience.
        Cancer. 2011; 117: 4381-4389
        • Hayes A.R.
        • Grossman A.B.
        The ectopic adrenocorticotropic hormone syndrome: rarely easy, always challenging.
        Endocrinol Metab Clin North Am. 2018; 47: 409-425
        • Isidori A.M.
        • Kaltsas G.A.
        • Pozza C.
        • et al.
        The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up.
        J Clin Endocrinol Metab. 2006; 91: 371-377
        • Ma Y.
        • Aitelli C.
        • Dobson R.W.
        • Konduri K.
        Ectopic adrenocorticotropic hormone syndrome: a diagnostic challenge and review of the literature.
        Proc (Bayl Univ Med Cent). 2010; 23: 426-428
        • Rindi G.
        • Inzani F.
        Neuroendocrine neoplasm update: toward universal nomenclature.
        Endocr Relat Cancer. 2020; 27: R211-R218
        • Davi M.V.
        • Cosaro E.
        • Piacentini S.
        • et al.
        Prognostic factors in ectopic Cushing’s syndrome due to neuroendocrine tumors: a multicenter study.
        Eur J Endocrinol. 2017; 176: 453-461
        • Ilias I.
        • Torpy D.J.
        • Pacak K.
        • Mullen N.
        • Wesley R.A.
        • Nieman L.K.
        Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institutes of Health.
        J Clin Endocrinol Metab. 2005; 90: 4955-4962
        • Kamp K.
        • Alwani R.A.
        • Korpershoek E.
        • Franssen G.J.H.
        • de Herder W.W.
        • Feelders R.A.
        Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors.
        Eur J Endocrinol. 2016; 174: 271-280
        • Morris L.F.
        • Harris R.S.
        • Milton D.R.
        • et al.
        Impact and timing of bilateral adrenalectomy for refractory adrenocorticotropic hormone-dependent Cushing’s syndrome.
        Surgery. 2013; 154 (discussion 1183–1174): 1174-1183
        • Neary N.M.
        • Lopez-Chavez A.
        • Abel B.S.
        • et al.
        Neuroendocrine ACTH-producing tumor of the thymus: experience with 12 patients over 25 years.
        J Clin Endocrinol Metab. 2012; 97: 2223-2230
        • Paleń-Tytko J.E.
        • Przybylik-Mazurek E.M.
        • Rzepka E.J.
        • et al.
        Ectopic ACTH syndrome of different origin-Diagnostic approach and clinical outcome: experience of one clinical centre.
        PLoS One. 2020; 15e0242679
        • Aniszewski J.P.
        • Young Jr., W.F.
        • Thompson G.B.
        • Grant C.S.
        • van Heerden J.A.
        Cushing syndrome due to ectopic adrenocorticotropic hormone secretion.
        World J Surg. 2001; 25: 934-940
        • Chow J.T.
        • Thompson G.B.
        • Grant C.S.
        • Farley D.R.
        • Richards M.L.
        • Young Jr., W.F.
        Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing’s syndrome: a review of the Mayo Clinic experience.
        Clin Endocrinol (Oxf). 2008; 68: 513-519
        • Valassi E.
        • Crespo I.
        • Gich I.
        • Rodríguez J.
        • Webb S.M.
        A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing’s syndrome.
        Clin Endocrinol (Oxf). 2012; 77: 735-742
        • Alberda W.J.
        • van Eijck C.H.
        • Feelders R.A.
        • Kazemier G.
        • de Herder W.W.
        • Burger J.W.
        Endoscopic bilateral adrenalectomy in patients with ectopic Cushing’s syndrome.
        Surg Endosc. 2012; 26: 1140-1145
        • Newell-Price J.
        • Trainer P.
        • Besser M.
        • Grossman A.
        The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states.
        Endocr Rev. 1998; 19: 647-672
        • Nieman L.K.
        • Biller B.M.
        • Findling J.W.
        • et al.
        The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline.
        J Clin Endocrinol Metab. 2008; 93: 1526-1540
        • Hernández I.
        • Espinosa-de-los-Monteros A.L.
        • Mendoza V.
        • et al.
        Ectopic ACTH-secreting syndrome: a single center experience report with a high prevalence of occult tumor.
        Arch Med Res. 2006; 37: 976-980
        • Stachowska B.
        • Kuliczkowska-Płaksej J.
        • Kałużny M.
        • Grzegrzółka J.
        • Jończyk M.
        • Bolanowski M.
        Etiology, baseline clinical profile and comorbidities of patients with Cushing’s syndrome at a single endocrinological center.
        Endocrine. 2020; 70: 616-628
        • Torpy D.J.
        • Mullen N.
        • Ilias I.
        • Nieman L.K.
        Association of hypertension and hypokalemia with Cushing’s syndrome caused by ectopic ACTH secretion: a series of 58 cases.
        Ann N Y Acad Sci. 2002; 970: 134-144
        • Wajchenberg B.L.
        • Mendonça B.
        • Liberman B.
        • Adelaide M.
        • Pereira A.
        • Kirschner M.A.
        Ectopic ACTH syndrome.
        J Steroid Biochem Mol Biol. 1995; 53: 139-151
        • Cheung N.W.
        • Boyages S.C.
        Failure of somatostatin analogue to control Cushing’s syndrome in two cases of ACTH-producing carcinoid tumours.
        Clin Endocrinol (Oxf). 1992; 36: 361-367
        • De Rosa G.
        • Testa A.
        • Liberale I.
        • Pirronti T.
        • Granone P.
        • Picciocchi A.
        Successful treatment of ectopic Cushing’s syndrome with the long-acting somatostatin analog octreotide.
        Exp Clin Endocrinol. 1993; 101: 319-325
        • Nieman L.K.
        • Biller B.M.
        • Findling J.W.
        • et al.
        Treatment of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline.
        J Clin Endocrinol Metab. 2015; 100: 2807-2831
        • Kim J.
        • Zimmerman M.A.
        • Hong J.C.
        Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors.
        J Gastrointest Oncol. 2020; 11: 601-608
        • Kim J.Y.
        • Hong S.M.
        • Ro J.Y.
        Recent updates on grading and classification of neuroendocrine tumors.
        Ann Diagn Pathol. 2017; 29: 11-16